Cephalothin group is a solid. This compound belongs to the 1,3-thiazines. These are organic compounds containing 1,3-thiazine, a six-member ring with a nitrogen and a sulfur atom in ring positions 1 and 3 respectively, as well as two double bonds. This substance is known to target beta-lactamase Toho-1 and D-alanyl-D-alanine carboxypeptidase.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cephalothin Group. |
| Tenofovir disoproxil | Cephalothin Group may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Cephalothin Group may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Cephalothin Group may increase the nephrotoxic activities of Tenofovir. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephalothin Group. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Cephalothin Group. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Cephalothin Group. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cephalothin Group. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Cephalothin Group. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cephalothin Group. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cephalothin Group. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Cephalothin Group. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Cephalothin Group. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cephalothin Group. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Cephalothin Group. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Cephalothin Group. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Cephalothin Group. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Cephalothin Group. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Cephalothin Group. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cephalothin Group. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Cephalothin Group. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Cephalothin Group. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Cephalothin Group. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Cephalothin Group. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Cephalothin Group. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cephalothin Group. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Cephalothin Group. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cephalothin Group. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Cephalothin Group. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cephalothin Group. |
| Pentamidine | The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Cephalothin Group. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Cephalothin Group. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cephalothin Group. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cephalothin Group. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Cephalothin Group. |
| Meloxicam | The risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Cephalothin Group. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Cephalothin Group. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cephalothin Group. |
| Etacrynic acid | The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cephalothin Group. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Cephalothin Group. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Cephalothin Group. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cephalothin Group. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Cephalothin Group. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Cephalothin Group. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cephalothin Group. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Cephalothin Group. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cephalothin Group. |
| Cefuroxime | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cephalothin Group. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Cephalothin Group. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Cephalothin Group. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of nephrotoxicity can be increased when Lumiracoxib is combined with Cephalothin Group. |
| Cefamandole | The risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Cephalothin Group. |
| Cefazolin | The risk or severity of nephrotoxicity can be increased when Cefazolin is combined with Cephalothin Group. |
| Cefonicid | The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Cephalothin Group. |
| Cefoperazone | The risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Cephalothin Group. |
| Cefoxitin | The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Cephalothin Group. |
| Ceftizoxime | The risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Cephalothin Group. |
| Magnesium salicylate | The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Cephalothin Group. |
| Salsalate | The risk or severity of nephrotoxicity can be increased when Salsalate is combined with Cephalothin Group. |
| Choline magnesium trisalicylate | The risk or severity of nephrotoxicity can be increased when Choline magnesium trisalicylate is combined with Cephalothin Group. |
| Cefepime | The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Cephalothin Group. |
| Cefacetrile | The risk or severity of nephrotoxicity can be increased when Cefacetrile is combined with Cephalothin Group. |
| Cefpodoxime | The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Cephalothin Group. |
| Antrafenine | The risk or severity of nephrotoxicity can be increased when Antrafenine is combined with Cephalothin Group. |
| Aminophenazone | The risk or severity of nephrotoxicity can be increased when Aminophenazone is combined with Cephalothin Group. |
| Antipyrine | The risk or severity of nephrotoxicity can be increased when Antipyrine is combined with Cephalothin Group. |
| Tiaprofenic acid | The risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Cephalothin Group. |
| Lopinavir | The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Cephalothin Group. |
| Etoricoxib | The risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Cephalothin Group. |
| Hydrolyzed Cephalothin | The risk or severity of nephrotoxicity can be increased when Hydrolyzed Cephalothin is combined with Cephalothin Group. |
| Oxyphenbutazone | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Oxyphenbutazone. |
| Latamoxef | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Latamoxef. |
| Nimesulide | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Nimesulide. |
| Benoxaprofen | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Benoxaprofen. |
| Metamizole | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Metamizole. |
| Zomepirac | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Zomepirac. |
| Ceftobiprole | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Ceftobiprole. |
| Cimicoxib | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Cimicoxib. |
| Ceftaroline fosamil | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Ceftaroline fosamil. |
| Lornoxicam | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Lornoxicam. |
| Zaltoprofen | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Zaltoprofen. |
| Azapropazone | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Azapropazone. |
| Parecoxib | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Parecoxib. |
| Salicylamide | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Salicylamide. |
| Kebuzone | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Kebuzone. |
| Isoxicam | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Isoxicam. |
| Indoprofen | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Indoprofen. |
| Ibuproxam | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Ibuproxam. |
| Floctafenine | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Floctafenine. |
| Fenbufen | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Fenbufen. |
| Etofenamate | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Etofenamate. |
| Epirizole | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Epirizole. |
| Cefaloridine | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Cefaloridine. |
| Cefminox | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Cefminox. |
| Dexibuprofen | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Dexibuprofen. |
| Droxicam | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Droxicam. |
| Tolfenamic acid | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Tolfenamic acid. |
| Firocoxib | The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Firocoxib. |